Fei Shen
Directeur/Membre du Conseil chez ArrePath, Inc.
Profil
Fei Shen is currently working as an Investment Director at Boehringer Ingelheim (Venture Capital) since 2020 and also as a Director at ArrePath, Inc. Dr. Shen's former job was as a Director at Rgenta Therapeutics, Inc.
Postes actifs de Fei Shen
| Sociétés | Poste | Début |
|---|---|---|
Boehringer Ingelheim (Venture Capital)
 Boehringer Ingelheim (Venture Capital) Investment ManagersFinance Boehringer Ingelheim (BIVF) is the venture capital arm of Boehringer Ingelheim International GmbH, itself a subsidiary of C.H. Boehringer Sohn AG & Co. KG. The firm was founded in 2010 and is headquartered in Ingelheim, Germany. It also has two US offices located in Fremont, California, and Cambridge, Massachusetts. | Private Equity Investor | 01/01/2020 |
ArrePath, Inc.
 ArrePath, Inc. Information Technology ServicesTechnology Services ArrePath, Inc. is an anti-infective drug discovery company that focuses on addressing the health challenge of drug-resistant infections. The platform's proof-of-concept has been demonstrated in studies published in Cell by ArrePath's scientific founder, Zemer Gitai, Ph.D., Edwin Grant Conklin Professor of Biology at Princeton University. The company is based in Princeton, NJ, and is funded by the Boehringer Ingelheim Venture Fund, Insight Partners, Innospark Ventures, Viva BioInnovator, Arimed Capital, PTX Capital, and Nor'easter Ventures. The company utilizes a proprietary machine learning-based platform to efficiently identify anti-infective agents with new mechanisms of action at the outset of the discovery process. This is achieved through a deep understanding and analysis of pathogen behavior. The CEO of the company is Lloyd J. Payne. | Directeur/Membre du Conseil | - |
Anciens postes connus de Fei Shen
| Sociétés | Poste | Fin |
|---|---|---|
Rgenta Therapeutics, Inc.
 Rgenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Rgenta Therapeutics, Inc. manufactures medicines for oncology and neurological disorders. The company was founded by Simon Xi, Travis Wager, and Zhiping Weng and is headquartered in Cambridge, MA. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Boehringer Ingelheim (Venture Capital)
Boehringer Ingelheim (Venture Capital) Investment ManagersFinance Boehringer Ingelheim (BIVF) is the venture capital arm of Boehringer Ingelheim International GmbH, itself a subsidiary of C.H. Boehringer Sohn AG & Co. KG. The firm was founded in 2010 and is headquartered in Ingelheim, Germany. It also has two US offices located in Fremont, California, and Cambridge, Massachusetts. | Finance |
Rgenta Therapeutics, Inc.
Rgenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Rgenta Therapeutics, Inc. manufactures medicines for oncology and neurological disorders. The company was founded by Simon Xi, Travis Wager, and Zhiping Weng and is headquartered in Cambridge, MA. | Health Technology |
ArrePath, Inc.
ArrePath, Inc. Information Technology ServicesTechnology Services ArrePath, Inc. is an anti-infective drug discovery company that focuses on addressing the health challenge of drug-resistant infections. The platform's proof-of-concept has been demonstrated in studies published in Cell by ArrePath's scientific founder, Zemer Gitai, Ph.D., Edwin Grant Conklin Professor of Biology at Princeton University. The company is based in Princeton, NJ, and is funded by the Boehringer Ingelheim Venture Fund, Insight Partners, Innospark Ventures, Viva BioInnovator, Arimed Capital, PTX Capital, and Nor'easter Ventures. The company utilizes a proprietary machine learning-based platform to efficiently identify anti-infective agents with new mechanisms of action at the outset of the discovery process. This is achieved through a deep understanding and analysis of pathogen behavior. The CEO of the company is Lloyd J. Payne. | Technology Services |
